Byotrol Share Discussion Threads

[playful] 03/12/2014 11:24

Lets hope 2015 is a great year for BYOT

[battlebus2] 03/12/2014 08:19

Another 100k bought, any overhang must be coming to an end given the buying from the recent results?

[shroder] 30/11/2014 11:41

I wonder if this will tip the scales in out favour, either way great news for NHS.

George Osborne confirms extra £2bn for NHS

[brownson] 29/11/2014 06:43

Consistent buying over last 2 days. Very encouraging. Quite a bit of stock to clear before we see much of a rise I suspect

[battlebus2] 28/11/2014 16:04

Buyers to the fore again today, you can sell 100k at 3.38 online atm.

[shroder] 28/11/2014 14:19

There does appear to be a change of sentiment in our favour. Should respond well once news starts to flow US/Europe ect.

[battlebus2] 28/11/2014 08:17

Yes good to see, mm's not keen to sell at 3.5p this morning so another good sign..

[brownson] 27/11/2014 16:52

thick end of 1 million shares bought. makes a pleasant change. Nice to see a similar performance tomorrow

[battlebus2] 27/11/2014 09:31

Fitted with a pace maker now :))

[maxk] 27/11/2014 09:15

Is that a pulse?

[shroder] 27/11/2014 09:07

Finncap were quite upbeat, indeed they reiterated their price target.

"We make no changes to our full-year forecasts and retain our 8.2p target price."

I have also been in direct contact with the company on one or two points, very pleased with the response and level of detail.

Looking forward to hearing about the new formula when ready.

[playful] 27/11/2014 08:30

Nice start to the morning :0)

[brownson] 26/11/2014 08:21

The problem with the company's approach is that you can only cut costs for so long. Eventually you have to make some sales. Those are sadly lacking

[shroder] 25/11/2014 11:50

I seem to remember we had this discussion before on EPA approval, this from 2006.



__________________________


Byotrol Secures EPA Approvals to Open Up North ...

Monday 31 July, 2006


Byotrol plc


Byotrol plc ('the Company'), the AIM-quoted anti-microbial technology business
has succeeded in obtaining approvals from the Environment Protection Agency
('EPA') in the United States for its technology to be used as a disinfectant,
sanitiser and anti-microbial product.

As part of this process, the EPA has approved the Company's claims that its
technology is effective against a range of micro-organisms including Salmonella,
Listeria, MRSA, E.coli and Avian Influenza.

The EPA is the legislative body in the USA which is responsible for protecting
human health and the environment. It regulates the approval of new technologies
and products for use in these areas, and the performance claims that can legally
be made on the product labels.

The approvals follow a 7 month review process undertaken by the EPA and allows
Byotrol to market disinfectants and sanitisers in the USA in the Company's
initially targeted markets in healthcare, food and industrial technology. As set
out in the Admission Document at the time of the AIM flotation, the EPA
registration represents an important milestone in the Company's commercial
strategy.

The approvals allow the Company to market its products in concentrate form as a
sanitiser and disinfectant for domestic use and for customers including
hospitals and other healthcare institutions, food processing plants and
agricultural facilities (including those subject to inspection by the US
Department of Agriculture), restaurants, retail operations, hotels, public
transport facilities, schools and universities, health clubs and spas.

The Company has identified significant demand for its products in these areas
based on discussions with a number of potential customers who have, until now,
been unable to trial or acquire Byotrol's products without the EPA approvals
that have now been obtained.

This latest clearance for Byotrol's technology comes days after the Company was
awarded CE Mark status for its products which allows it to market its technology
to the medical sector on a pan European basis.

Byotrol's Deputy Chairman Stephen Falder commented: 'The EPA acceptance of our
anti-microbial claims is a very important springboard for key market sectors in
the USA. We had originally anticipated that, at this stage, we would receive EPA
acceptance for 5 to 7 market-specific claims but I am delighted to say that we
have been able to obtain in excess of 20 approvals. Each approval allows us to
sell our product in concentrate form to customers in a particular category or
market sector. This is considerably ahead of our plan and a significant step
forward for the Company following the detailed and complex work of the
registration process.'

According to the Global Biocides Report, the worldwide biocide market was valued
in excess of $5.9 billion in 2005, with the USA the largest user of biocides,
and is currently growing at around 4% per annum.

According to David McRobbie, Chief Executive Officer of Byotrol plc, 'EPA
approval is one of the most significant milestones in the Company's development
to date. The approval, which was achieved on time and within budget, opens up
the vast United States market for our technology and allows us to sell our
products into a broader spectrum of sectors than we had originally anticipated.
This builds on our progress in the UK and Europe where we have started to sell
our products in a broad range of markets, from care homes and medical
laboratories through to food processing and industrial coatings.'

[mr.oz] 25/11/2014 10:59

www.bdaily.co.uk/finance/25-11-2014/daresburys-byotrols-turnover-is-down/

[maxk] 25/11/2014 10:56

Perhaps a musical interlude would be appropriate?

[mudbath] 25/11/2014 10:42

The carrot of future profitability continues to be dangled.
The interim results do indicate margin pressure in all sectors,something that the BOD has chosen not to quantify.The news regarding quality issues in Asia is for me disquieting as this represents a weakness in management controls.
US approval and/or a significant new contract("THE BIG ONE")could well turn things around.
Whilst we wait though,the upwardly revised cash pile commences to diminish.
As long as the PI does benefit from any success we can wait a while longer.
We are susceptible to being "dished" though, should any breakthrough ever occur.
But that applies to most tiny AIM outfits anyway;its just a risk that we accommodate.
Overall then,a touch disappointing imo.

[shroder] 25/11/2014 08:25

It will be interesting to hear about the new formaulation, perhaps this will help pry open the doors of the NHS.



o New formulation, particularly applicable to consumer markets

o Superior performance claims to current formulations

o Complies with forthcoming European biocide and labelling regulations

o Marketing programme now launched in European Union countries

[shroder] 25/11/2014 07:57

Morning folks

There's not much in there to light any fires with the exception of perhaps Dr Francis appointment.

Underlying figures are good but still progress is slow, as bb says we need a large contract to get things moving.

It's encouraging but not exciting.

[brownson] 25/11/2014 07:44

The problem is, there's nothing here to attract attention. Any potential investor asks himself, can I afford to wait before buying byotrol and the answer is a resounding "yes", so no likelihood of a rise. Buyers need to be afraid of missing the boat.

[battlebus2] 25/11/2014 07:22

Well pleased with those results, progress to profitability is being made and the new board appointment is an excellent one imv. Cash position is still a concern but i had suspected as much. One big U.S. contract after approval and that 10p by y/e December 2015 will be easy..

[a.fewbob] 25/11/2014 00:00

we had uckin better b! I have lost all patience with these. we would have had better sales if the dip sticks from the apprentice were running the show.

[battlebus2] 24/11/2014 23:44

Also a large buy later, anyway fingers crossed for tomorrow, i'm hopeful we are making progress.

[brownson] 24/11/2014 10:47

largish sell this am. Hope that's not an indicator of what's to come tomorrow